Mandate

Vinge advises CMA Microdialysis in connection with the sale of pre-clinical business

July 04, 2011

Vinge has advised CMA Microdialysis in connection with the sale of its pre-clinical business to Harvard Biosciences. The main shareholders of MCA Microdialysis are Investor Growth Capital and Bure Equity. In connection with the transaction, the company has changed its name to Dipylon Medical.

Vinge’s team consisted of partner Johan Winnerblad together with, among others, fellow partner Fredrik Dahl and associate Claes Henriksson.

Related

Vinge advises Sertion in connection with the acquisition of Kiefer System Group

Vinge has advised Sertion AB (“Sertion”) in connection with the acquisition of Kiefer System Group.
October 10, 2025

Vinge advises Main Capital and Aritma in connection with the acquisition of Programekonomi

Vinge has advised Aritma International AS (“Aritma”), a Norwegian bank-connectivity and financial automation software provider, in connection with the acquisition of Programekonomi Svenska Aktiebolag.
October 09, 2025

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025